Abstract

Background: Menopause and aging deteriorate the metabolic profile, but little is known about how they independently contribute to structural changes in coronary arteries. We compared a broad cardiometabolic risk profile of women according to their menopausal status and investigated if menopause per se is associated with presence of coronary artery calcium (CAC) in the ELSA-Brasil.
Materials and Methods: All participants, except perimenopausal women, who had menopause <40 years or from non-natural causes or reported use of hormone therapy were included. Sample was stratified according to menopause and age categories (premenopause ≤45 years, premenopause >45 years, and postmenopause); their clinical profile and computed tomography-determined CAC were compared using Kruskal–Wallis and chi squared test for frequencies. Associations of CAC (binary variable) with menopause categories adjusted for traditional and nontraditional covariables were tested using logistic regression.
Results: From 2,047 participants 51 ± 9 years of age, 1,175 were premenopausal (702 ≤ 45 years) and 872 were postmenopausal women. Mean values of anthropometric variables, blood pressure, lipid and glucose parameters, branched-chain amino acids (BCAA), and homeosthasis model assessment (HOMA-IR), as well as frequencies of morbidities, were more favorable in premenopausal, particularly in younger ones. In crude analyses, CAC >0 was associated with triglyceride-rich lipoprotein remnants, dense low-density lipoprotein, BCAA, and other variables, but not with HOMA-IR. Menopause was independently associated with CAC >0 (odds ratios 2.37 [95% confidence interval 1.17–4.81]) when compared to the younger premenopausal group.
Conclusion: Associations of menopause with CAC, independent of traditional and nontraditional cardiovascular risk factors, suggest that hormonal decline per se may contribute to calcium deposition in coronary arteries.

Get full access to this article

View all available purchase options and get full access to this article.

References

1. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2011 update: A report from the American Heart Association. Circulation 2011;123:e18–e209.
2. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: A guideline from the American Heart Association. Circulation 2011;123:1243–1262.
3. Maas AHEM, Van der Schouw YT, Regitz-Zagrosek V, et al. Red alert for women's heart: The urgent need for more research and knowledge on cardiovascular disease in women. Eur Heart J 2011;32:1362–1368.
4. Berger JS, Elliott L, Gallup D, et al. Sex differences in mortality following acute coronary syndromes. JAMA 2009;302:874–882.
5. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention what a difference a decade makes. Circulation 2011;124:2145–2154.
6. Bonithon-Koop C, Scarabin PY, Darne B, et al. Menopause-related changes in lipoproteins and some other cardiovascular risk factors. Int J Epidemiol 1990;19:42–48.
7. Cifkova R, Krajcoviechova A. Dyslipidemia and cardiovascular disease in women. Curr Cardiol Rep 2015;17:609.
8. Fonseca MIH, Silva IT, Ferreira SRG. Impact of menopause and diabetes on atherogenic lipid profile: Is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women? Diabetol Metab Syndr 2017;9:22.
9. Brown WV, Gulati M, Lundberg GP. JCL roundtable: Cardiovascular disease risk reduction in menopausal women. J Clin Lipidol 2017;11:316–324.
10. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990;12:321–331.
11. Li Z, McNamara JR, Fruchart JC, et al. Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J Lipid Res 1996;37:1886–1896.
12. Campos H, McNamara JR, Wilson PW, et al. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1988;67:30–35.
13. Anagnostis P, Stevenson JP, Crook D, et al. Effects of menopause, gender and age on lipids and high-density lipoprotein cholesterol subfractions. Maturitas 2015;81:62–68.
14. Derby CA, Crawford SL, Pasternak RC, et al. Lipid changes during the menopause transition in relation to age and weight. The Study of Women's Health Across the Nation. Am J Epidemiol 2009;169:1352–1361.
15. Khoudary SR, Ceponiene I, Samargandy S, et al. HDL (high-density lipoprotein) metrics and atherosclerotic risk in women. Do menopause characteristics matter? MESA. Arterioscler Thromb Vasc Biol 2018;38:2236–2244.
16. Khoudary SR, Wang L, Brooks MM, et al. Increase HDL-C level over the menopausal transition is associated with greater atherosclerotic progression. J Clin Lipidol 2016;10:962–969.
17. Fonseca MIH, Almeida-Pititto B, Bensenor IM, et al. Changes in lipoprotein subfractions following menopause in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Maturitas 2019;130:32–37.
18. McNamara JR, Shah PK, Nakajima K, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: Results from the Framingham Heart Study. Atherosclerosis 2001;154:229–236.
19. Ianuzzi A, Gentile M, Ianuzzo G, et al. Atherogenic lipoprotein subfractions and carotid atherosclerosis in menopausal women. Angiology 2018;69:666–671.
20. Zhang ZY, Monleon D, Verhamme P, et al. Branched-chain amino acids as critical switches in health and disease. Hypertension 2018;72:1012–1022.
21. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448–453.
22. Libert DM, Nowacki AS, Natowicz MR. Metabolomic analysis of obesity, metabolic syndrome, and type 2 diabetes: Amino acid and acylcarnitine levels change along a spectrum of metabolic wellness. Peer J 6:e5410.
23. Hu W, Sun L, Gong Y, et al. Relationship between branched-chain amino acids, metabolic syndrome, and cardiovascular risk profile in a Chinese population: A cross-sectional study. Int J Endocrinol 2016;2016:8173905.
24. Flores-Guerrero JL, Oste MCJ, Kieneker LM, et al. Plasma branched-chain amino acids and risk of incident type 2 diabetes: Results from the PREVEND prospective cohort study. J Clin Med 2018;7:pii: E513.
25. Tobias DK, Lawler PR, Harada PH, et al. Circulating branched-chain amino acids and incident cardiovascular disease in a prospective cohort of US women. Circ Genom Precis Med 2018;11:e002157.
26. Iida M, Harada S, Kurihara A, et al. Profiling of plasma metabolites in postmenopausal women with metabolic syndrome. Menopause 2016;23:749–758.
27. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583–1587.
28. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system. Lessons learned and unanswered questions. J Am Coll Cardiol 2006;47:1741–1753.
29. Salpeter SR, Walsh JME, Ormiston TM, et al. Meta-analysis: Effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538–554.
30. Warren MP, Halpert S. Hormone replacement therapy: Controversies, pros and cons. Best Pract Res Clin Endocrinol Metab 2004;18:317–332.
31. Penn CA, Chan J, Mesaros C, et al. Association of serum androgens and coronary artery calcium scores in women. Fertil Steril 2019;112:586–593.
32. Mackey RH, Kuller LH, Sutton-Tyrrell K, et al. Hormone therapy, lipoprotein subclasses, and coronary calcification: The Healthy Women Study. Arch Intern Med 2005;165:510–515.
33. Budoff MJ, Chen GP, Hunter CJ, et al. Effects of hormone replacement in progression of coronary calcium as measured by electron beam tomography. J Womens Health (Larchmt) 2005;14:410–417.
34. Miller VM, Naftolin F, Asthana S, et al. The Kronos Early Estrogen Prevention Study (KEEPS): What have we learned? Menopause 2019;26:1071–1084.
35. Becker A, Leber A, Ziegler F, et al. Comparison of progression of coronary calcium in postmenopausal women on versus not on estrogen/progestin therapy. Am J Cardiol 2007;99:374–378.
36. Collins P, Webb CM, Villiers TJ, et al. Cardiovascular risk assessment in women: An update. Climacteric 2016;19:329–336.
37. Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy—An update. Climacteric 2016;19:313–315.
38. Lobo RA, Pickar JH, Stevenson JC, et al. Back to the future: Hormone replacement therapy as part of prevention strategy for women at the onset of menopause. Atherosclerosis 2016;254:282–290.
39. Hecht H, Blaha MJ, Berman DS, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus from the Society of Computed Tomography. J Cardiovasc Comput Tomogr 2017;11:157–168.
40. Erbel R, Mohlenkamp S, Moebus S, et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: The Heinz Nixdorf Recall Study. J Am Coll Cardiol 2010;56:1397–1406.
41. Shaw LJ, Min JK, Nasir K, et al. Sex differences in calcified plaque and long-term cardiovascular mortality: Observations from the CAC Consortium. Eur Heart J 2018;39:3727–3735.
42. Ouyang P, Vaidya D, Dobs A, et al. Sex hormone levels and subclinical atherosclerosis in post-menopausal women: The Multi-ethnic Study of Atherosclerosis. Atherosclerosis 2009;204:255–261.
43. Munir JA, Wu H, Bauer K, et al. The perimenopausal atherosclerosis transition: Relationship between calcified and noncalcified coronary, aortic, and carotid atherosclerosis and risk factors and hormone levels. Menopause 2012;19:10–15.
44. Subramanya V, Zhao D, Ouyang P, et al. Association of endogenous sex hormone levels with coronary artery calcium progression among post-menopausal women in the Multi-Ethnic Study of Atherosclerosis (MESA). J Cardiovasc Comput Tomogr 2019;13:41–47.
45. Schmidt MI, Duncan BB, Mill JG, et al. Cohort profile: Longitudinal Study of Adult Health (ELSA-Brasil). Int J Epidemiol 2015;44:68–75.
46. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
47. Kulkarni KR. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med 2006;26:787–802.
48. Kulkarni KR, Garber DW, Marcovina SM, et al. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 1994;35:159–168.
49. Kulkarni KR, Marcovina SM, Krauss RM, et al. Quantification of HL2 and HDL3 cholesterol by the vertical auto profile-II (VAP-II) methodology. J Lipid Res 1997;38:2353–2364.
50. Azevedo CF, Rochite CE, Lima JAC. Coronary artery calcium score and coronary computed tomographic angiography for cardiovascular risk stratification. Arq Bras Cardiol 2012;98:559–568.
51. Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: The multi-ethnic study of atherosclerosis (MESA). Eur Heart J 2018;39:2401–2408.
52. Hoffmann U, Massaro JM, D'Agostino Sr RB, et al. Cardiovascular event prediction and risk reclassification by coronary, Aortic, and valvular calcification in the Framingham heart study. J Am Heart Assoc 2016:5:e003144.
53. Shaw LJ, Giambrone AE, Blaha MJ, et al. Long-term prognosis after coronary artery calcification testing in asymptomatic patients: A cohort study. Ann Int Med 2015;163:14e21.
54. Nakanishi R, Li D, Blaha MJ, et al. The relationship between coronary artery calcium score and the long-term mortality among patients with minimal or absent coronary artery risk factors. Int J Cardiol 2015;185:275e281.
55. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: A report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation 2007;115:402–426.
56. Shemesh J, Motro M, Morag-Koren N, et al. Relation of coronary artery calcium to cardiovascular risk in patients with combined diabetes mellitus and systemic hypertension. Am J Cardiol 2012;109:844e850.
57. Ravennik G, Jeppsson S, Johnell O, et al. A longitudinal study of the perimenopausal transition: Altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995;21:103–113.
58. Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009;54:2366–2373.
59. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation 2020;142:e506–e532.
60. Yan H, Yang W, Zhou F, et al. Estrogen improves insulin sensitivity and supresses gluconeogenesis via the transcription factor foxol. Diabetes 2019;68:291–304.
61. Handgraaf S, Riant E, Fabre A, et al. Prevention of obesity and insulin resistance by estrogens requires ERα activation function-2 (ERαAF-2), whereas ERαAF-1 is dispensable. Diabetes 2013;62:4098–4108.
62. Christian RC, Harrington S, Edwards WD, et al. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab 2002;87:1062–1067.
63. Refaie MR, Sayed-Ahmed NA, Bakr Am, et al. Aging is an inevitable risk factor for insulin resistance. J T U Med Sc 2006;1: 30–41.
64. Rodrigues TC, Biavatti K, Almeida FK, et al. Coronary artery calcification is associated with insulin resistance index in patients with type 1 diabetes. Braz J Med Biol Res 2010;43:1084–1087.
65. Ruiz-Canela M, Toledo E, Clish CB, et al. Plasma branched-chain amino acids and incident cardiovascular disease in the PREDIMED trial. Clin Chem 2016;62:582–592.
66. Mackey RH, Kuller LH, Sutton-Tyrrell K, et al. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. Am J Cardiol 2002;90:71i–76i.
67. Prado KB, Shugg S, Backstrand JR. Low-density lipoprotein particle number predicts coronary artery calcification in asymptomatic adults at intermediate risk of cardiovascular disease. J Clin Lipidol 2011;5:408–413.
68. Bittencourt MS, Santos RD, Staniak H, et al. Relation of fasting triglyceride-rich lipoprotein cholesterol to coronary artery calcium score (from the ELSA-Brasil study). Am J Cardiol 2017;119:1352–1358.

Information & Authors

Information

Published In

cover image Journal of Women's Health
Journal of Women's Health
Volume 31Issue Number 1January 2022
Pages: 23 - 30
PubMed: 34520264

History

Published online: 12 January 2022
Published in print: January 2022
Published ahead of print: 14 September 2021

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Marília I.H. Fonseca, MD, PhD
Department of Epidemiology, School of Public Health, University of Sao Paulo, Sao Paulo, Brazil.
Bianca de Almeida-Pititto, MD, PhD
Department of Epidemiology, School of Public Health, University of Sao Paulo, Sao Paulo, Brazil.
Department of Preventive Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil.
Márcio S. Bittencourt, MD, PhD
Internal Medicine Department, University of Sao Paulo, Sao Paulo, Brazil.
Faculdade Israelita de Ciencias da Saude Albert Einstein, Sao Paulo, Brazil.
Isabela M. Bensenor, MD, PhD
Internal Medicine Department, University of Sao Paulo, Sao Paulo, Brazil.
Paulo A. Lotufo, MD, PhD
Internal Medicine Department, University of Sao Paulo, Sao Paulo, Brazil.
Sandra R.G. Ferreira, MD, PhD [email protected]
Department of Epidemiology, School of Public Health, University of Sao Paulo, Sao Paulo, Brazil.

Notes

Address correspondence to: Sandra R.G. Ferreira, MD, PhD, Department of Epidemiology, School of Public Health, University of São Paulo, Av. Dr. Arnaldo, 715, São Paulo, SP 01246-904, Brazil [email protected]

Authors' Contributions

M.I.H.F. and B.d.A.-P.: conceptualization, methodology, analysis, visualization, and writing/revision. M.S.B., I.M.B., and P.A.L.: writing/revision. S.R.G.F.: conceptualization, visualization, writing/revision, and supervision. All authors contributed to the revision of this article. All authors read and approved the final article.

Author Disclosure Statement

M.I.H.F., B.d.A.-P., I.M.B., P.A.L., and S.R.G.F. declare no conflicts of interest for this article. M.S.B. reports grants from Sanofi, other from GE HealthCare, and other from Boston Scientific, outside the submitted work.

Funding Information

The ELSA-Brasil is supported by the Brazilian Ministry of Health (Department of Science and Technology) and Ministry of Science, Technology and Innovation (FINEP, Projects and Studies Finance), Grant Nos. 01 06 0010.00; 01 06 0212.00; 01 06 0300.00; 01 06 0278.00; 01 06 0115.00; and 01 06 0071.00 and CNPq (the National Council for Scientific and Technological Development). No funding for this specific analysis has been provided.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top